Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors
- 1 February 1999
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 31 (1-2) , 1210-1213
- https://doi.org/10.1016/s0041-1345(98)02094-6
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Basiliximab (Simulect???) is Efficacious in Reducing the Incidence of Acute Rejection Episodes in Renal Allograft Patients: Results at 12 MonthsTransplantation, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- PROLONGED ACTION OF A CHIMERIC INTERLEUKIN-2 RECEPTOR (CD25) MONOCLONAL ANTIBODY USED IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1995
- THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG-TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2Transplantation, 1994
- EARLY VERSUS LATE ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1993
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992